Covid-19 Vaccination

Latest news, daily rates, information and updates

Last updated 27 November, 2022 10:30 CEST

As the coronavirus vaccine rolls out across the globe on this page you will find all our latest Covid-19 vaccine updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

12,989,299,811

+8,864,420 reported yesterday

Number of fully vaccinated globally

5,017,475,454

+3,711,913 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

0.9%

+10% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 12,989,299,811 1,710.4 6607 %
China 3,442,080,000 2,471.5 9123 % CanSino, IMBCAMS, KCONVAC, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001
India 2,199,012,704 1,625.7 7029 % Corbevax, Covaxin, Novavax, Oxford/AstraZeneca, Sputnik V
United States 616,172,307 1,883.4 6877 % Johnson&Johnson, Moderna, Pfizer/BioNTech
Brazil 473,461,305 2,260.3 8244 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Indonesia 437,022,061 1,632.7 6374 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Japan 345,319,115 2,729.2 8139 % Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Bangladesh 331,485,953 2,054.4 7754 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Pakistan 301,236,601 1,419.5 6230 % CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Vietnam 258,223,943 2,702.8 8776 % Abdala, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Mexico 209,673,612 1,661.6 6335 % CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Germany 187,878,955 2,265.6 7656 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Valneva
Russia 182,824,700 1,252.8 5379 % EpiVacCorona, Sputnik V
Philippines 163,734,141 1,535.2 6821 % Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Iran 154,329,909 1,837.4 6955 % CanSino, Covaxin, COVIran Barekat, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V
Turkey 152,475,057 1,852.2 6459 % Pfizer/BioNTech, Sinovac, Turkovac
United Kingdom 151,248,820 2,274.8 7632 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
France 150,055,693 2,240.1 7922 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Italy 142,683,882 2,361.1 7938 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Thailand 142,635,014 2,054.4 7704 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
South Korea 129,600,358 2,509.9 8657 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Argentina 110,283,256 2,478.6 8511 % CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Egypt 98,019,706 957.8 3847 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Spain 95,763,061 2,049.6 8700 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Canada 94,801,622 2,558.1 8549 % Johnson&Johnson, Medicago, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Colombia 87,566,541 1,763.7 7348 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Peru 85,618,847 2,676.5 8854 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Malaysia 72,265,904 2,242.4 8541 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Saudi Arabia 67,701,901 2,009.0 7496 % Oxford/AstraZeneca, Pfizer/BioNTech
Nigeria 67,216,328 343.2 1590 % Oxford/AstraZeneca
Uzbekistan 65,334,146 1,982.5 5005 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik Light, Sputnik V, ZF2001
Taiwan 63,733,433 2,699.4 8701 % Medigen, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Chile 62,564,376 3,340.5 9446 % CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Myanmar 62,259,560 1,159.2 5032 % Oxford/AstraZeneca, Sinopharm/Beijing
Australia 58,470,395 2,339.5 8714 % Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Poland 57,401,382 1,511.4 5945 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Nepal 57,015,910 2,029.9 7948 % Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Morocco 55,229,652 1,532.9 6521 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Ethiopia 52,192,941 477.8 3506 % Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Cambodia 43,600,091 2,683.1 8939 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Cuba 42,269,794 3,728.1 8817 % Abdala, Soberana Plus, Soberana02
Sri Lanka 39,982,306 1,845.1 6774 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
South Africa 37,951,019 656.8 3380 % Johnson&Johnson, Pfizer/BioNTech
Venezuela 37,860,994 1,311.4 4949 % Abdala, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V
Ecuador 37,260,948 2,181.0 8246 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Netherlands 36,104,942 2,095.3 6940 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Ukraine 31,683,310 710.0 3411 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Belgium 27,610,574 2,417.3 8020 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Rwanda 26,054,302 2,117.9 7252 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Portugal 25,139,266 2,445.0 8674 % Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Uganda 25,120,036 588.0 2940 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
United Arab Emirates 24,922,054 2,530.0 9941 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Sweden 24,836,133 2,438.9 7501 % Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Mozambique 24,676,660 836.6 4500 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Tanzania 24,435,483 433.9 3253 % Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing
Angola 22,297,104 723.7 2536 % Oxford/AstraZeneca
Greece 21,869,556 2,038.6 7123 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Kenya 21,202,827 412.6 1943 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Kazakhstan 20,918,681 1,144.6 5802 % QazVac, Sinopharm/Beijing, Sputnik V
Hong Kong 19,927,049 2,635.9 8936 % Pfizer/BioNTech, Sinovac
Austria 19,768,871 2,234.5 7489 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Guatemala 19,670,066 1,140.4 4002 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Ghana 19,302,116 648.4 2803 % Oxford/AstraZeneca, Sputnik V
Iraq 19,181,396 499.1 2034 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Czechia 18,532,808 1,744.2 6486 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Cote d'Ivoire 18,304,332 730.2 3517 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Israel 18,286,159 2,058.4 6931 % Moderna, Pfizer/BioNTech
Romania 16,827,486 864.1 4167 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hungary 16,530,488 1,692.2 6352 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Switzerland 16,399,384 1,925.6 7057 % Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech
Honduras 16,107,153 1,680.0 5915 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Dominican Republic 16,089,476 1,514.0 5700 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Tajikistan 15,441,380 1,696.7 5626 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Algeria 15,267,442 361.5 1535 % Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Belarus 15,177,629 1,600.1 6734 % KoviVac/Chumakov, Sinopharm/Beijing, Sputnik Light, Sputnik V
Tunisia 14,827,155 1,282.0 5519 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Bolivia 14,499,985 1,277.2 5387 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Singapore 14,326,294 2,540.7 8876 % Moderna, Novavax, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Azerbaijan 13,857,111 1,393.7 4891 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Denmark 13,192,325 2,275.5 8228 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Finland 13,027,929 2,361.0 7876 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Zimbabwe 12,161,598 842.3 3276 % Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Zambia 12,146,645 700.0 4720 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Norway 12,106,503 2,278.1 7629 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Costa Rica 11,913,344 2,382.9 8407 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
New Zealand 11,843,091 2,424.1 8464 % Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Nicaragua 11,829,966 1,829.7 8897 % Abdala, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Soberana02, Sputnik Light, Sputnik V
Afghanistan 11,820,186 318.0 2741 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
El Salvador 11,289,175 1,758.2 6766 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Laos 11,111,066 1,527.2 7178 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Ireland 11,058,235 2,278.4 8349 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Jordan 10,057,975 1,010.2 4578 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Paraguay 9,390,960 1,350.0 5050 % Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Uruguay 8,747,863 2,536.1 8392 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Panama 8,622,442 2,064.3 7545 % Oxford/AstraZeneca, Pfizer/BioNTech
Serbia 8,534,688 1,222.4 4695 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Kuwait 8,209,255 1,984.2 8063 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Sudan 8,179,010 195.7 1085 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Guinea 7,467,372 601.5 2329 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Qatar 7,462,980 2,682.9 10049 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Oman 7,107,964 1,471.8 6310 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Slovakia 7,074,781 1,298.8 5074 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Lebanon 5,773,446 843.0 3506 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Mongolia 5,492,919 1,732.7 6863 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Croatia 5,311,360 1,298.8 5499 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Somalia 5,029,419 335.1 1949 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Democratic Republic of Congo 4,756,847 56.6 342 % Oxford/AstraZeneca
Syria 4,649,982 265.7 1180 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Bulgaria 4,595,136 654.2 2953 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Niger 4,534,313 202.0 1328 % Oxford/AstraZeneca, Sinopharm/Beijing
Lithuania 4,517,703 1,619.5 6737 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Malawi 4,323,160 238.3 1239 % Johnson&Johnson, Oxford/AstraZeneca
Sierra Leone 3,940,973 515.1 2862 % Oxford/AstraZeneca, Sinopharm/Beijing
Chad 3,876,928 250.5 2333 % Sinopharm/Beijing
Palestine 3,741,181 733.4 3478 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Burkina Faso 3,740,943 179.5 1164 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Libya 3,709,205 555.4 1840 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Benin 3,687,739 321.1 2377 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Liberia 3,549,394 736.5 6126 % Oxford/AstraZeneca
Bahrain 3,475,665 2,214.6 7816 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Kyrgyzstan 3,332,471 527.6 2145 % Sinopharm/Beijing, Sputnik V
Togo 3,286,253 416.6 1820 % Oxford/AstraZeneca
Mauritania 3,251,620 738.4 3234 % Oxford/AstraZeneca, Sinopharm/Beijing
Slovenia 2,996,643 1,449.5 5912 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Mali 2,990,301 156.7 866 % Oxford/AstraZeneca
Albania 2,966,256 1,034.8 4400 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Georgia 2,930,677 785.5 3420 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Latvia 2,895,716 1,503.1 6779 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Botswana 2,871,301 1,273.8 6098 % Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Mauritius 2,580,909 2,039.8 7727 % Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Senegal 2,469,499 155.8 691 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Moldova 2,165,600 610.7 2999 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Estonia 2,076,308 1,571.9 6414 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
South Sudan 1,991,329 181.4 1730 % Johnson&Johnson, Oxford/AstraZeneca
Bhutan 1,928,471 2,556.3 8946 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Cameroon 1,893,318 75.1 498 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
North Macedonia 1,861,054 893.5 4022 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik V
Kosovo 1,836,846 995.4 4470 % Oxford/AstraZeneca, Pfizer/BioNTech
Madagascar 1,809,232 68.9 556 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Cyprus 1,792,897 1,415.4 5096 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Armenia 1,761,529 596.8 2659 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik Light, Sputnik V
Macao 1,663,581 2,633.8 9918 % Pfizer/BioNTech, Sinopharm/Beijing
Central African Republic 1,586,764 340.0 2994 % Covaxin, Oxford/AstraZeneca
Trinidad and Tobago 1,580,898 1,137.5 5158 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Fiji 1,547,282 1,751.3 7239 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Jamaica 1,495,422 509.5 2506 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Luxembourg 1,348,647 2,219.2 7618 % Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Malta 1,343,194 2,777.9 9743 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Brunei 1,273,212 2,741.2 9575 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Bosnia and Herzegovina 1,242,203 373.7 1528 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Lesotho 1,077,116 510.9 4139 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Guyana 1,017,969 1,306.8 5926 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Maldives 950,776 1,843.7 7464 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Namibia 950,468 388.2 2101 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Yemen 898,257 31.5 165 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Cape Verde 853,757 1,535.6 5547 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Congo 833,078 9.9 78 % Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Gambia 815,861 357.8 1567 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Iceland 805,469 2,278.1 8207 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Eswatini 773,579 680.9 4319 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Papua New Guinea 693,524 80.6 351 % Oxford/AstraZeneca
Montenegro 679,171 1,091.3 4577 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Guinea-Bissau 673,091 359.1 2094 % Oxford/AstraZeneca, Sinopharm/Beijing
Solomon Islands 625,956 958.8 3896 % Oxford/AstraZeneca
Northern Cyprus 617,389 1,657.5 7409 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Comoros 598,000 718.5 3087 % Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Gabon 569,829 268.9 1213 % Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Suriname 505,699 878.0 4130 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Belize 500,424 1,306.3 5753 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
French Polynesia 497,169 1,790.4 6701 % Johnson&Johnson, Pfizer/BioNTech
Equatorial Guinea 484,554 370.2 1590 % Sinopharm/Beijing, Sinovac
Haiti 470,964 42.3 200 % Johnson&Johnson, Moderna
New Caledonia 469,705 1,612.1 6319 % Pfizer/BioNTech
Samoa 448,784 2,288.2 9058 % Oxford/AstraZeneca
Bahamas 362,109 939.0 4273 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Barbados 318,263 1,110.3 5395 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Vanuatu 293,584 1,003.1 4500 % Oxford/AstraZeneca
Curacao 256,029 1,601.7 6253 % Moderna, Pfizer/BioNTech
Djibouti 253,257 264.1 2214 % CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Jersey 242,600 2,250.5 7550 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sao Tome and Principe 226,808 1,074.8 4875 % Oxford/AstraZeneca
Seychelles 214,152 2,213.2 8392 % Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Tonga 205,799 1,947.1 7269 % Oxford/AstraZeneca
Isle of Man 189,994 2,259.8 7981 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Aruba 173,953 1,643.5 7925 % Pfizer/BioNTech
Guernsey 157,708 2,515.0 2172 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Andorra 154,195 2,002.4 6945 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cayman Islands 148,160 2,308.7 9372 % Oxford/AstraZeneca, Pfizer/BioNTech
Antigua and Barbuda 136,512 1,417.8 6479 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Bermuda 132,042 2,064.2 7450 % Oxford/AstraZeneca, Pfizer/BioNTech
Saint Lucia 122,552 673.8 3012 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Gibraltar 119,578 3,546.4 12279 % Oxford/AstraZeneca, Pfizer/BioNTech
Faeroe Islands 103,894 0 % Moderna, Pfizer/BioNTech
Grenada 90,251 809.8 3488 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Greenland 79,745 1,423.4 6872 % Moderna, Pfizer/BioNTech
Liechtenstein 72,911 1,923.3 6978 % Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech
Turks and Caicos Islands 72,837 1,933.8 8041 % Pfizer/BioNTech
Saint Vincent and the Grenadines 72,687 659.5 2842 % Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik Light, Sputnik V
Dominica 67,639 944.3 4280 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Sint Maarten (Dutch part) 65,095 1,601.2 6522 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Saint Kitts and Nevis 64,225 1,206.7 5062 % Oxford/AstraZeneca, Pfizer/BioNTech
Monaco 49,980 1,292.1 6026 % Pfizer/BioNTech
San Marino 47,100 1,394.1 7233 % Pfizer/BioNTech, Sputnik V
Turkmenistan 41,993 7.0 16 % EpiVacCorona, Oxford/AstraZeneca, QazVac, Sinopharm/Beijing, Sputnik V, ZF2001
Nauru 25,172 1,981.4 6758 % Oxford/AstraZeneca
Anguilla 24,408 1,351.0 5725 % Oxford/AstraZeneca, Pfizer/BioNTech
Burundi 21,264 1.9 17 % Johnson&Johnson, Sinopharm/Beijing
Wallis and Futuna 17,959 1,136.0 4298 % Moderna
Bonaire Sint Eustatius and Saba 7,391 275.7 621 % Moderna, Pfizer/BioNTech
Tuvalu 4,772 405.0 0 % Oxford/AstraZeneca
Montserrat 4,544 847.9 3611 % Oxford/AstraZeneca
Falkland Islands 4,322 1,070.1 4251 % Oxford/AstraZeneca
Saint Helena 3,107 393.1 0 % Oxford/AstraZeneca
Micronesia (country) 0 0.0 0 %
Eritrea 0 0.0 0 %
Timor-Leste 0 0.0 0 %
Marshall Islands 0 0.0 0 %
Vatican 0 0.0 0 %

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 47

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of COVID-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation in some regions.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
20 Oct, 2022: Emergency Use Authorization given by EU
5 Oct, 2022: Emergency Use Authorization given by Japan
9 Sep, 2022: Emergency Use Authorization given by Singapore
29 Sep, 2022: Emergency Use Authorization given by Australia
9 Sep, 2022: Emergency Use Authorization given by Canada
30 Aug, 2022: Emergency Use Authorization given by Japan
19 Aug, 2022: Emergency Use Authorization given by Canada
8 Jul, 2022: Emergency Use Authorization given by the US
17 Jun, 2022: Emergency Use Authorization given by the US
17 May, 2022: Emergency Use Authorization given by the US
8 Apr, 2022: Emergency Use Authorization given by Australia
29 Mar, 2022: Emergency Use Authorization given by the US
24 Mar, 2022: Complete Approval given by Japan
23 Feb, 2022: Emergency Use Authorization given by South Korea
30 Jan, 2022: Complete Approval given by Qatar
28 Jan, 2022: Emergency Use Authorization given by Australia
21 Jan, 2022: Emergency Use Authorization given by Japan
09 Jan, 2022: Complete Approval given by Qatar
06 Jan, 2022: Emergency Use Authorization given by Malaysia
06 Jan, 2022: Complete Approval given by Brazil
04 Jan, 2022: Emergency Use Authorization given by US
22 Dec, 2021: Complete Approval given by UK
11 Dec, 2021: Emergency Use Authorization given by Singapore
10 Dec, 2021: Complete Approval given by Switzerland
09 Dec, 2021: Emergency Use Authorization given by US
08 Dec, 2021: Emergency Use Authorization given by South Africa
07 Dec, 2021: Complete Approval given by Spain
05 Dec, 2021: Emergency Use Authorization given by Australia
02 Dec, 2021: Emergency Use Authorization given by Italy
28 Nov, 2021: Complete Approval given by Egypt
19 Nov, 2021: Complete Approval given by Canada
19 Nov, 2021: EUA Approval given by US
10 Nov, 2021: Complete Approval given by Japan
9 Nov, 2021: Complete Approval given by Canada
01 Nov, 2021: Emergency Use Authorization given by South Africa
29 Oct, 2021: Emergency Use Authorization given by US
27 Oct, 2021: Emergency Use Authorization given by Australia
8 Oct, 2021: Emergency Use Authorization given by Malaysia
22 Sep, 2021: Emergency Use Authorization given by US
16 Sep, 2021: Complete Approval given by Canada
23 Jun, 2021: Emergency Use Authorization given by Australia
15 Jul, 2021: Emergency Use Authorization given by Indonesia
24 Jun, 2021: Emergency Use Authorization given by Thailand
21 Jun, 2021: Complete Approval given by New-Zealand
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Complete Approval given by US
12 Jun, 2021: Emergency Use Authorization given by Vietnam
11 Jun, 2021: Complete Approval given by Brazil
4 Jun, 2021: Emergency Use Authorization given by UK
2 Jun, 2021: Emergency Use Authorization given by Zambia
31 May, 2021: Emergency Use Authorization given by Pakistan
31 May, 2021: Emergency Use Authorization given by Italy
28 May,2021: Complete Approval given by EU
27 May, 2021: Emergency Use Authorization given by Bangladesh
13 May, 2021: Emergency Use Authorization given by United Arab Emirates
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
21 Mar, 2021: Emergency Use Authorization given by Libya
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
25 Dec, 2020: Emergency Use Authorization given by Ireland
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 30

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of COVID-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
20 Oct, 2022: Emergency Use Authorization given by EU
20 Oct, 2022: Emergency Use Authorization given by Australia
24 Aug, 2022: Emergency Use Authorization given by Singapore
18 Jul, 2022: Emergency Use Authorization given by Australia
14 Jul, 2022: Emergency Use Authorization given by the Canada
17 Jun, 2022: Emergency Use Authorization given by the US
31 May, 2022: Emergency Use Authorization given by the Philippines
13 May, 2022: Emergency Use Authorization given by the Switzerland
17 Apr, 2022: Emergency Use Authorization given by the Taiwan
14 Apr, 2022: Emergency Use Authorization given by the UK
29 Mar, 2022: Emergency Use Authorization given by the US
17 Mar, 2022: Complete Approval given by Canada
03 Mar, 2022: Complete Approval given by EU
16 Feb, 2022: Emergency Use Authorization given by Australia
08 Feb, 2022: Emergency Use Authorization given by Colombia
2 Feb, 2022: Complete Approval given by the US
16 Dec, 2021: Complete Approval given by Japan
8 Dec, 2021: Emergency Use Authorization given by Australia
19 Nov, 2021: Emergency Use Authorization given by US
12 Nov, 2021: Complete Approval given by Canada
20 Oct, 2021: Emergency Use Authorization given by the US
5 Oct, 2021: Emergency Use Authorization given by EU
16 Sep, 2021: Complete Approval given by Canada
5 Sep, 2021: Emergency Use Authorization given by Australia
4 Sep, 2021: Emergency Use Authorization given by Philippines
19 Aug, 2021: Emergency Use Authorization given by Mexico
13 Aug, 2021: Emergency Use Authorization given by US
9 Aug, 2021: Emergency Use Authorization given by Australia
5 Aug, 2021: Emergency Use Authorization given by Malaysia
30 Jul, 2021: Emergency Use Authorization given by Lithuania
2 Jul, 2021: Emergency Use Authorization given by Italy
26 Jul, 2021: Emergency Use Authorization given by Bhutan
9 Jul, 2021: Emergency Use Authorization given by Saudia Arabia
4 Jul, 2021: Emergency Use Authorization given by United Arab Emirates
2 Jul, 2021: Emergency Use Authorization given by Indonesia
30 Jun, 2021: Emergency Use Authorization given by India
30 Jun, 2021: Emergency Use Authorization given by Bangladesh
29 Jun, 2021: Emergency Use Authorization given by Vietnam
8 Jun, 2021: Emergency Use Authorization given by Maldives
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
6 May, 2021: Emergency Use Authorization given by Taiwan
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
21 Mar, 2021: Emergency Use Authorization given by Libya
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4% 54

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, schedule and SARS-CoV-2 variant. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
1 Nov, 2022: Complete Approval given by EU
23 May, 2022: Complete Approval given by EU
01 Feb, 2022: Emergency Use Authorization given by Thailand
27 Jan, 2022: Emergency Use Authorization given by India
15 Jan, 2022: Complete Approval given by Oman
17 Nov, 2021: Emergency Use Authorization given by Malaysia
14 Nov, 2021: Emergency Use Authorization given by Bahrain
28 Jul, 2021: Emergency Use Authorization given by New Zealand
2 Jun, 2021: Emergency Use Authorization given by Zambia
21 May, 2021: Emergency Use Authorization given by Japan
21 Mar, 2021: Emergency Use Authorization given by Libya
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
12 Feb, 2021: Emergency Use Authorization given by Cambodia
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
24 Jan, 2021: Emergency Use Authorization given by Ecuador
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 90.4% 18

Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest.

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
9 Nov, 2022: Emergency Use Authorization given by the UK
19 Oct, 2022: Emergency Use Authorization given by the US
16 Sep, 2022: Expanded Emergency Use Authorization given by Taiwan
16 Sep, 2022: Emergency Use Authorization given by Israel
13 Sep, 2022: Complete Approval given by South Africa
12 Sep, 2022: Conditional Marketing Authorization given by EU
19 Aug, 2022: Emergency Use Authorization given by the Switzerland
5 Jul, 2022: Conditional Marketing Authorization given by UK
19 Aug, 2022: Emergency Use Authorization given by the US
18 Aug, 2022: Emergency Use Authorization given by New Zealand
17 Aug, 2022: Emergency Use Authorization given by New Zealand
12 Aug, 2022: Emergency Use Authorization given by South Korea
26 Jul, 2022: Emergency Use Authorization given by Australia
13 Jul, 2022: Emergency Use Authorization given by the US
5 Jul, 2022: Conditional Marketing Authorization given by EU
23 Jun, 2022: Emergency Use Authorization given by Taiwan
19 Apr, 2022: Complete Approval given by Japan
"13 Apr, 2022: Emergency Use Authorization given by Switzerland
" "08 Apr, 2022: Emergency Use Authorization given by Thailand
" "22 Mar, 2022: Emergency Use Authorization given by India
" "10 Mar, 2022: Restricted Emergency Use Authorization given by India
" "17 Feb, 2022: Emergency Use Authorization given by Canada
" "14 Feb, 2022: Emergency Use Authorization given by Singapore
" "03 Feb, 2022: Emergency Use Authorization given by New Zealand
" "03 Feb, 2022: Complete Approval given by UK
" "19 Jan, 2022: Emergency Use Authorization given by Australia
" "13 Jan, 2022: Complete Approval given by South Korea
" "28 Dec, 2021: Restricted Emergency Use Authorization given by India
" "24 Dec, 2021: Emergency Use Authorization given by Netherlands
" "20 Dec, 2021: Emergency Use Authorization given by EU
" "17 Dec, 2021: Emergency Use Listing given by WHO
" "18 Nov, 2021: Emergency Use Authorization given by Philippine
" 1 Nov, 2021: Emergency Use Authorization given by Indonesia
Today

Johnson & Johnson 44,325 1 2 - 8°C 66.0% 31

Adenoviral vaccine able to confer nearly 70% protection against all COVID-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
20 Jun, 2022: Complete Approval given by Japan
27 Feb, 2022: Emergency Use Listing (EUL) given by WHO
27 Feb, 2022: Emergency Use Authorization given by the US
24 Nov, 2021: Complete Approval given by Canada
21 Oct, 2021: Emergency Use Authorization given by the US
16 Sep, 2021: Emergency Use Authorization given by Iran
07 Sep, 2021: Emergency Use Authorization given by Indonesia
07 Aug, 2021: Emergency Use Authorization given by India
28 Jul, 2021: Emergency Use Authorization given by Zimbabwe
15 Jul, 2021: Emergency Use Authorization given by Vietnam
7 Jul, 2021: Provisional approval given by New Zealand
5 Jul, 2021: Emergency Use Authorization given by Ukraine
25 Jun, 2021: Provisional approval given by Australia
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Emergency Use Authorization given by Bangladesh
11 Jun, 2021: Emergency Use Authorization given by Chile
8 Jun, 2021: Emergency Use Authorization given by Kuwait
8 Jun, 2021: Emergency Use Authorization given by Maldives
2 Jun, 2021: Emergency Use Authorization given by Zambia
28 May, 2021: Conditional Marketing Authorization given by UK
28 May, 2021: Emergency Use Authorization given by Mexico
20 Apr, 2021: Emergency Use Authorization given by Philippines
8 Apr, 2021: Emergency Use Authorization given by Tunisia
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
1 Apr, 2021: Emergency Use Authorization given by Brazil
21 Mar, 2021: Emergency Use Authorization given by Libya
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.7% 27

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
18 Oct, 2022: Emergency Use Authorization given by Philippines
3 Aug, 2022: Emergency Use Authorization given by Hong Kong
13 Jul, 2022: Emergency Use Authorization given by Brazil
25 Jun, 2022: Emergency Use Authorization given by South Africa
"14 Mar, 2022: Emergency Use Authorization given by Philippine
" "04 Mar, 2022: Emergency Use Authorization given by Malaysia
" "05 Feb, 2022: Emergency Use Authorization given by Thailand
" "01 Feb, 2022: Emergency Use Authorization given by Thailand
" "20 Jan, 2022: Emergency Use Authorization given by Brazil
" "20 Nov, 2021: Emergency Use Authorization given by Hong Kong
" "17 Nov, 2021: Emergency Use Authorization given by Malaysia
" "12 Nov, 2021: Emergency Use Authorization given by Pakistan
" "1 Oct, 2021: Emergency Use Authorization given by Malaysia
" "9 Sep, 2021: Emergency Use Authorization given by Chile
" "25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
" "17 Jul, 2021: Emergency Use Authorization given by Sri Lanka
" "3 Jul, 2021: Emergency Use Authorization given by South Africa
" "24 Jun, 2021: Emergency Use Authorization given by Oman
" "11 Jun, 2021: Emergency Use Authorization given by China
" "6 Jun, 2021: Emergency Use Authorization given by Bangladesh
" "4 Jun, 2021: Emergency Use Authorization given by Nepal
" "2 Jun, 2021: Emergency use listing (EUL) given by WHO
" "27 Apr, 2021: Emergency Use Authorization given by Egypt
" "10 Apr, 2021: Emergency Use Authorization given by Pakistan
" "9 Apr, 2021: Emergency Use Authorization given by Panama
" "10 Mar, 2021: Complete Approval given by Ukraine
" "10 Mar, 2021: Emergency Use Authorization given by Zimbabwe
" "05 Mar, 2021: Complete Approval given by Tunisia
" "2 Mar, 2021: Emergency Use Authorization given by Malaysia
" "26 Feb, 2021: Emergency Use Authorization given by Hong Kong
" "26 Feb, 2021: Emergency Use Authorization given by Ecuador
" "22 Feb, 2021: Emergency Use Authorization given by Philippines
" "22 Feb, 2021: Emergency Use Authorization given by Thailand
" "13 Feb, 2021: Emergency Use Authorization given by Cambodia
" "11 Feb, 2021: Emergency Use Authorization given by Mexico
" "8 Feb, 2021: Emergency Use Authorization given by China
" "6 Feb, 2021: Emergency Use Authorization given by Lao People's Democratic Republic
" "6 Feb, 2021: Emergency Use Authorization given by Uruguay
" "5 Feb, 2021: Emergency Use Authorization given by Colombia
" "21 Jan, 2021: Emergency Use Authorization given by Chile
" "18 Jan, 2021: Emergency Use Authorization given by Brazil
" "13 Jan, 2021: Emergency Use Authorization given by Turkey
" "11 Jan, 2021: Emergency Use Authorization given by Indonesia
"
Today

Gamaleya - Sputnik V 33,758 2 2 - 8°C 91.4% 74

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all COVID-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
02 Apr, 2022: Complete Approval given by Russia
04 Feb, 2022: Complete Approval given by Russia
31 Oct, 2021: Emergency Use Authorization given by Cambodia
25 Aug, 2021: Emergency Use Authorization given by Indonesia
21 Jul, 2021: Emergency Use Authorization given by Chile
15 Jul, 2021: Emergency Use Authorization given by Nigeria
24 Jun, 2021: Emergency Use Authorization given by Oman
5 Jun, 2020: Conditional Approval given by Brazil
15 May, 2021: Emergency Use Authorization given by Republic of Ecuador
13 May, 2021: Emergency Use Authorization given by Maldives
30 Apr, 2021: Emergency Use Authorization given by Turkey
30 Apr, 2021: Emergency Use Authorization given by Albania
27 Apr, 2021: Emergency Use Authorization given by Bangladesh
20 Apr, 2021: Emergency Use Authorization given by Nepal
12 Apr, 2021: Emergency Use Authorization given by India
1 Apr, 2021: Emergency Use Authorization given by Panama
30 Mar, 2021: Emergency Use Authorization given by Mali
26 Mar, 2021: Emergency Use Authorization given by Antigua
26 Mar, 2021: Emergency Use Authorization given by Barbuda
23 Mar, 2021: Emergency Use Authorization given by Vietnam
22 Mar, 2021: Emergency Use Authorization given by Mauritius
19 Mar, 2021: Emergency Use Authorization given by Cameroon
19 Mar, 2021: Emergency Use Authorization given by Philippines
19 Mar, 2021: Emergency Use Authorization given by Republic of Seychelles
12 Mar, 2021: Emergency Use Authorization given by Azerbaijan
11 Mar, 2021: Emergency Use Authorization given by Namibia
10 Mar, 2021: Emergency Use Authorization given by Jordan
10 Mar, 2021: Emergency Use Authorization given by Kenya
10 Mar, 2021: Emergency Use Authorization given by Morocco
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
7 Mar, 2021: Emergency Use Authorization given by Macedonia
7 Mar, 2021: Emergency Use Authorization given by North Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
4 Mar, 2021: Emergency Use Authorization given by Iraq
4 Mar, 2021: Emergency Use Authorization given by Laos
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
26 Feb, 2021: Emergency Use Authorization given by Republic of Moldova
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
23 Feb, 2021: Emergency Use Authorization given by Kyrgyzstan
23 Feb, 2021: Emergency Use Authorization given by Guyana
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
12 Feb, 2021: Emergency Use Authorization given by Saint Vincent and the Grenadines
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
9 Feb, 2021: Emergency Use Authorization given by Mongolia
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
14 Jan, 2021: Temporary Registration given by Kazakhstan
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
31 Dec, 2020: Emergency Use Authorization given by Serbia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: EUA given by Russia
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 9

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all COVID-19 and 90% efficacy in preventing severe COVID-19 with just a single dose.

Early Approval - 25 June 2020
Trial Start Date - 15 September 2020
Result Publication Date - 01 February 2021
10 Nov, 2022: Emergency Use Authorization given by Morocco
4 Sep, 2022: Emergency Use Authorization given by China
1 Jul, 2022: Emergency Use Authorization given by Malaysia
19 May, 2022: Emergency Use Listing given by WHO
22 Mar, 2022: Emergency Use Authorization given by Indonesia
22 Mar, 2022: Emergency Use Authorization given by Malaysia
19 Feb, 2022: Complete approval given by China
07 Sep, 2021: Emergency Use Authorization given by Indonesia
16 Jun, 2021: Complete approval given by Ecuador
15 Jun, 2021: Emergency Use Authorization given by Malaysia
12 Jun, 2021: Emergency Use Authorization given by Argentina
8 Apr, 2021: Emergency Use Authorization given by Chile
22 Mar, 2021: Emergency Use Authorization given by Hungary
12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Today

Sinopharm 60,000 2 2 - 8°C 86.0% 36

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 10 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 31 December 2020
9 May, 2022: Complete Approval given by Myanamar
22 Mar, 2022: Emergency Use Authorization given by Indonesia
07 Feb, 2022: Emergency Use Authorization given by South Africa
05 Feb, 2022: Emergency Use Authorization given by Thailand
28 Dec, 2021: Emergency Use Authorization given by UAE
12 Nov, 2021: Emergency Use Authorization given by Pakistan
2 Oct, 2021: Emergency Use Authorization given by Argentina
21 Aug, 2021: Emergency Use Authorization given by Mexico
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
24 Aug, 2021: Emergency Use Authorization given by Nigeria
19 Aug, 2021: Emergency Use Authorization given by Kenya
16 Jul, 2021: Emergency Use Authorization given by Malaysia
12 Jul, 2021: Emergency Use Authorization given by Tunisia
9 Jul, 2021: Emergency Use Authorization given by Trinidad and Tobago
18 Jun, 2021: Emergency Use Authorization given by Gambia
11 Jun, 2021: Emergency Use Authorization given by China
7 Jun, 2021: Emergency Use Authorization given by Philippines
4 June, 2021: Emergency Use Authorization given by Vietnam
2 Jun, 2021: Emergency Use Authorization given by Zambia
29 May, 2021: Emergency Use Authorization given by Bangladesh
28 May, 2021: Emergency Use Authorization given by Thailand
07 May, 2021: Emergency Use Authorization given by WHO
29 Apr, 2021: Emergency Use Authorization given by Indonesia
20 Mar, 2021: Emergency Use Authorization given by Sri Lanka
16 Mar, 2021: Emergency Use Authorization given by Maldives
11 Mar, 2021: Emergency Use Authorization given by Iran
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
1 Mar, 2021: Emergency Use Authorization given by Venezuela
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
18-Feb, 2021: Emergency Use Authorization given by Nepal
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

Bharat Biotech 25,800 2 2 - 8°C 81.0% 13

Adjuvanted inactivated vaccine produced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.

Early Approval - 03 January 2021
Trial Start Date - 16 November 2020
Result Publication Date - 01 March 2021
26 Apr, 2022: Emergency Use Authorization given by India
11 Feb, 2022: Emergency Use Authorization given by Malaysia
27 Jan, 2022: Emergency Use Authorization given by India
27 Dec, 2021: Emergency Use Authorization given by India
12 Nov, 2021: Emergency Use Authorization given by Bahrain
10 Nov, 2021: Emergency Use Authorization given by Hong Kong
10 Nov, 2021: Emergency Use Authorization given by Hong Kong
8 Nov, 2021: Emergency Use Authorization given by Trinidad and Tobago
3 Nov, 2021: Emergency Use Authorization given by WHO
2 Nov, 2021: Emergency Use Authorization given by Guyana
20 Apr, 2021: Emergency Use Authorization given by Philippines
6 Apr, 2021: Emergency Use Authorization given by Mexico
26 Mar, 2021: Complete Approval given by Mauritius
21 Mar, 2021: Emergency Use Authorization given by Nepal
04 Mar, 2021: Emergency Use Authorization given by Zimbabwe
19 Feb, 2021: Emergency Use Authorization given by Iran
3 Jan, 2021: Restricted Emergency Use Authorization given by India
Today

Gamaleya - Sputnik Light 110 1 2 - 8°C 79.4% 23

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, showed 79.4% efficacy from 28 days after the injection was administered as part of Russia’s mass vaccination program.

Early Approval - 06 May 2021
Trial Start Date - 15 January 2021
Result Publication Date - 06 May 2021
7 Feb, 2022: Restricted Emergency Use Authorization given by India
29 Dec, 2021: Complete Approval given by Tunisia
6 Dec, 2021: Emergency Use Authorization given by Argentina
30 Nov, 2021: Emergency Use Authorization given by UAE
23 Nov, 2021: Emergency Use Authorization given by Laos
23 Nov, 2021: Emergency Use Authorization given by San Marino
31 Oct, 2021: Emergency Use Authorization given by Cambodia
6 Oct, 2021: Emergency Use Authorization given by UAE
24 Sep, 2021: Emergency Use Authorization given by Egypt
16 Sep, 2021: Emergency Use Authorization given by Iran
06 Sep, 2021: Complete Approval given by Armenia
23 Aug, 2021: Emergency Use Authorization given by Philippines
15 Jul, 2021: Complete Approval given by Kazakhstan
25 Jun, 2021: Emergency Use Authorization given by Kyrgyzstan
11 Jun, 2021: Emergency Use Authorization given by Mongolia
7 Jun, 2021: Emergency Use Authorization given by Republic of the Congo
3 Jun, 2021: Emergency Use Authorization given by Belarus
2 Jun, 2021: Emergency Use Authorization given by Mauritius
31 May, 2021: Emergency Use Authorization given by Palestine
21 May, 2021: Emergency Use Authorization given by Nicaragua
15 May, 2021: Emergency Use Authorization given by Venezuela
12 May, 2021: Emergency Use Authorization given by Angola
11 May, 2021: Emergency Use Authorization given by Bahrain
6 May, 2021: Complete Approval given by Russia
Today

Cadila Healthcare Ltd - ZyCoV-D 28,000 2 2 - 8°C 66.6% 1

ZyCoV-D is the first plasmid DNA, needle-free vaccine against COVID-19, showing 66.6% efficacy after the third injection was administered in over 28,000 volunteers at more than 50 clinical sites spread across India.

Early Approval - 20 August 2021
Trial Start Date - 20 January 2021
Result Publication Date - 01 July 2021
26 Apr, 2022: Emergency Use Authorization given by India
20 Aug, 2021: Emergency Use Authorization given by India
Today

Biological E Ltd - CORBEVAX 3,000 2 2 - 8°C 90.0% 2

CORBEVAX is a recombinant protein sub-unit vaccine, developed from the receptor binding domain (RBD) of the spike protein on the virus’s surface combined with Dynavax’s CpG 1018 adjuvant with alum. It Showed >90% efficacy against Wuhan strain and >80% efficacy against Delta Strain.

Early Approval - 28 December 2021
Trial Start Date - 01 January 1970
Result Publication Date - 01 January 1970
10 August, 2022: Emergency Use Authorization given by India
5 June, 2022: Emergency Use Authorization given by India
26 Apr, 2022: Emergency Use Authorization given by India
29 Mar, 2022: Complete Approval given by Botswana
28 Dec, 2021: Restricted Emergency Use Authorization given by India
28 Dec, 2021: Restricted Emergency Use Authorization given by India
Today

Medicago Inc - COVIFENZ 753 2 2 - 8°C 71% 1

COVIFENZ is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs) using Coronavirus-Like Particle (CoVLP) technology and is co-administered with GSK’s pandemic adjuvant. The vaccination regimen calls for two doses given intramuscularly 21 days apart. The vaccine is stored at 2 °C to 8 °C.

Early Approval - 07 December 2021
Trial Start Date - 19 November 2020
Result Publication Date - 24 February 2022
24 Feb, 2022: Complete Approval given by Canada
Today

Valneva SE - VLA2001 4 2 2 - 8°C 95% 4

VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.

Early Approval - 18 October 2021
Trial Start Date - 26 April 2021
Result Publication Date - 01 March 2022
19 Aug, 2022: Emergency Use Authorization given by WHO
24 Jun, 2022: Complete Approval given by EU
16 May, 2022: Emergency Use Authorization given by UAE
14 Apr, 2022: Complete Approval given by UK
1 Mar, 2022: Emergency Use Authorization given by Bahrain
Today

Moderna Inc - Spikevax Bivalent Original/Omicron BA.1 4 1 8°C to -50°C 94.1% 7

Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1). It is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Early Approval - 08 June 2022
Trial Start Date - 28 May 2021
Result Publication Date - 12 August 2022
16 Sep, 2022: Emergency Use Authorization given by the EU
12 Sep, 2022: Complete Approval given by Japan
1 Sep, 2022: Emergency Use Authorization given by Canada
30 Aug, 2022: Provisional approval given by Australia
29 Aug, 2022: Temporary Authorization given by Switzerland
12 Aug, 2022: Conditional Approval given by UK
Today

Pfizer/BioNTech - Comirnaty bivalent Original/Omicron (BA.1) 1 1 2 - 8°C 95% 4

Comirnaty bivalent Original/Omicron (BA.1) is a bivalent vaccine that contains Comirnaty and a vaccine candidate targeting the Omicron variant of concern (BA.1). It is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Early Approval - 03 September 2022
Trial Start Date - 25 January 2022
Result Publication Date - 03 September 2022
28 Oct, 2022: Provisional Approval given by the Australia
10 Oct, 2022: Temporary Authorization given by Switzerland
12 Sep, 2022: Emergency Use Authorization given by the EU
3 Sep, 2022: Conditional Approval given by UK
Today

Moderna Inc - Covid-19 mRNA [Omicron Ba.4/Ba.5] (Bivalent) Vaccine 5 1 2 - 8°C 4

BA.4/.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222 targets the BA.4/.5 subvariants of Omicron. 50 µg booster dose indicated for adults over 18 years of age who have received either a primary series or an initial booster of any of the authorized or approved COVID-19 vaccines. The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/.5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus.

Early Approval - 31 August 2022
Trial Start Date - 28 May 2021
Result Publication Date - 31 August 2022
3 Nov, 2022: Emergency Use Authorization given by Canada
1 Nov, 2022: Emergency Use Authorization given by Japan
26 Oct, 2022: Emergency Use Authorization given by the Taiwan
23 Oct, 2022: Interim Authorization given by the Singapore
20 Oct, 2022: Emergency Use Authorization given by the EU
12 Oct, 2022: Emergency Use Authorization given by the US
31 Aug, 2022: Emergency Use Authorization given by the US
Today

Pfizer/BioNTech - Comirnaty Bivalent Original/Omicron BA.4/BA.5 1 2 - 8°C 6

Omicron BA.4/BA.5 Bivalent Vaccine combines 15-µg of mRNA encoding the wild-type spike protein found in the Original Pfizer-BioNTech COVID-19 Vaccine and 15-µg of mRNA encoding the spike protein of the OmicronBA.4/BA.5 subvariants. 30-µg booster dose of Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) approved for individuals ages 12 years and older

Early Approval - 01 January 1970
Trial Start Date - 31 August 2022
Result Publication Date - 31 August 2022
10 Nov, 2022: Emergency Use Authorization given by the UK
26 Oct, 2022: Emergency Use Authorization given by the Taiwan
25 Oct, 2022: EInterim Authorization given by the Singapore
12 Oct, 2022: Emergency Use Authorization given by the US
7 Oct, 2022: Emergency Use Authorization given by Canada
5 Oct, 2022: Emergency Use Authorization given by Japan
16 Sep, 2022: Emergency Use Authorization given by the EU
31 Aug, 2022: Emergency Use Authorization given by the US
Today

Bharat Biotech Ltd - iNCOVACC 3 2 2 - 8°C 1

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a prefusion stabilized spike protein. It has been specifically formulated to allow intranasal delivery as nasal drops. iNCOVACC received approval under Restricted Use in Emergency Situation for ages 18 and above.

Early Approval - 15 August 2021
Trial Start Date - 31 August 2021
Result Publication Date - 06 September 2022
6 Sep, 2022: Restricted Emergency Use Authorization given by India
Today

Suzhou Abogen Biosciences Co Ltd - AWcorna 28,000 2 2 - 8°C 83.58% 1

The vaccine is presented in 0.5 mL prefilled syringe, with mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2 as the active substance.

Early Approval - 30 September 2022
Trial Start Date - 22 July 2021
Result Publication Date - 30 September 2022
30 Sep, 2022: Emergency Use Authorization given by Indonesia
Today

PT Bio Farma - Indovac 900 2 2 - 8°C 1

The Indovac vaccine contains the recombinant Receptor-Binding Domain (RBD) protein S of the SARS-Cov-2 virus, is a COVID-19 vaccine with a recombinant protein subunit platform.

Early Approval - 01 January 1970
Trial Start Date - 01 September 2022
Result Publication Date - 30 September 2022
30 Sep, 2022: Emergency Use Authorization given by Indonesia
Today

PT Biotis Pharmaceutical Indonesia - Inavac 4 2 2 - 8°C 1

The Inavac vaccine is a COVID-19 vaccine with an inactivated virus platform developed by researchers at Airlangga University and produced and registered by PT Biotis Pharmaceuticals Indonesia (PT Biotis).

Early Approval - 04 November 2022
Trial Start Date - 28 June 2022
Result Publication Date - 01 November 2022
01 Nov, 2022: Emergency Use Authorization given by Indonesia
Today

Shenzhen Kangtai Biological Products Co Ltd - Kconvac 2 2 - 8°C 2

Coronavirus Disease  2019 (COVID-19) vaccine (Kconvac/ Kconecavac) is a inactivated vaccine composed of SARS-CoV-2 virus antigen

Early Approval - 01 January 1970
Trial Start Date - 01 January 1970
Result Publication Date - 15 May 2021
21 Feb, 2022: Emergency Use Authorization given by China
11 Jan, 2022: Emergency Use Authorization given by Indonesia
03 Nov, 2021: Emergency Use Authorization given by Indonesia
15 May, 2021: Emergency Use Authorization given by China
Today

SK Bioscience Ltd - SKYCovione 4 2 2 - 8°C 1

SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine with combination of GSK’s pandemic adjuvant.

Early Approval - 29 June 2022
Trial Start Date - 30 August 2021
Result Publication Date - 29 June 2022
29 Jun, 2022: Complete Approval given by South Korea
Today

Federal Research Center for Research and Development of Immunobiological Preparations - KoviVac 32 2 2 - 8°C 1

KoviVac is an inactivated whole-virion concentrated purified coronavirus vaccine

Early Approval - 01 January 1970
Trial Start Date - 07 July 2021
Result Publication Date - 20 February 2021
20 Feb, 2021: Complete Approval given by Russia
Today

PT Bio Farma - Cov2Bio 1 2 2 - 8°C 65.30% 1

Cov2Bio is a inactivated vaccine composed of SARS-CoV-2 virus antigen

Early Approval - 11 January 2021
Trial Start Date - 01 January 1970
Result Publication Date - 11 January 2021
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Center for Genetic Engineering and Biotechnology - Abdala 48 3 2 - 8°C 2

Abdala is a vaccine targeting SARS-CoV-2 virus receptor binding domain recombinant protein

Early Approval - 01 January 1970
Trial Start Date - 22 March 2021
Result Publication Date - 11 June 2021
29 Dec, 2021: Emergency Use Authorization given by Mexico
11 Jul, 2021: Emergency Use Authorization given by Cuba
Today

HDT Bio Corp - Gemcovac 2 2 - 8°C 1

Gemcovac is an in-vitro transcribed self-amplifying mRNA encoding for the S-protein of SARS-CoV-2 vaccine

Early Approval - 11 January 2021
Trial Start Date - 01 January 1970
Result Publication Date - 28 June 2022
28 Jun, 2022: Emergency Use Authorization given by India
Today

The State Research Center of Virology and Biotechnology VECTOR - EpiVacCorona 100 2 2 - 8°C 1

EpiVacCorona is a synthetic peptide antigen based vaccine . It contains protein S of the SARS-CoV-2 virus, conjugated to the carrier protein

Early Approval - 01 January 1970
Trial Start Date - 27 July 2020
Result Publication Date - 13 October 2020
13 Oct, 2020: Complete Approval given by Russia
Today

Chongqing Zhifei Biological Products Co Ltd - Zifivax 50 2 2 - 8°C 2

 Zifivax is a recombinant protein subunit vaccine composed of new coronavirus spike glycoprotein receptor binding region NCP-RBD protein

Early Approval - 22 December 2020
Trial Start Date - 22 June 2020
Result Publication Date - 01 March 2021
10 Mar, 2021: Emergency Use Authorization given by China
1 Mar, 2021: Complete Approval given by Uzbekistan
Today

Livzon Pharmaceutical Group Co Ltd - V-01 10 2 2 - 8°C 61.35% 1

V-01 is a recombinant SARS-CoV-2 fusion protein vaccine

Early Approval - 16 February 2022
Trial Start Date - 03 November 2021
Result Publication Date - 02 September 2022
2 Sep, 2022: Emergency Use Authorization given by China
Today

Sanofi - Vidprevtyn 247 1 2 - 8°C 76.1%  1

Vidprevtyn is a recombinant baculovirus vaccine and comprises of recombinant S-protein COVID-19 antigen expressed in Baculo virus expression system

Early Approval - 13 June 2022
Trial Start Date - 08 December 2021
Result Publication Date - 10 November 2021
10 Nov, 2022: Emergency Use Authorization given by EU
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)